View clinical trials related to Diabetic Retinopathy.
Filter by:the aim of this study is to assess the impact of duration of DM on OCTA parameters in diabetic patients without clinical Diabetic retinopathy.
In this study, researchers want to learn about the safety of BAY3283142 after a single dose and multiple doses in participants with mild to moderate high blood pressure. The study treatment called BAY3283142 helps to relax blood vessels. It is currently under development for the treatment of chronic kidney disease (CKD) and nonproliferative diabetic retinopathy (NPDR). CKD is a condition in which the kidneys' ability to work gradually decrease over time. NPDR is a condition in which high blood glucose levels cause damage to the blood vessels of the retina, which is a tissue at the back of the eyes. During this study, participants will take either different doses of the study drug BAY3283142 as tablets by mouth or a placebo. A placebo looks like the study drug but does not have any medicine in it. At the start of this study, the study doctor will check the medical history and current medications of the participants. They will also perform a complete health check on all the participants. Researchers will collect blood and urine samples from the participants at different time points to assess the safety and effects of BAY3283142. Each treatment scheme will consist of three doses that are given in a consecutive manner. For the first 7 days, participants will receive a lower dose of BAY3283142 in each treatment scheme. The middle and the higher dose of each treatment scheme will be given for 14 days each. Participants will not know which treatment (placebo or BAY3283142) they will be given, but the study doctor will know which group received which treatment. A participant can be in the study for 10 weeks. This study will be conducted on men or postmenopausal women participants with mild to moderate high blood pressure who may not directly benefit from treatment with BAY3283142. However, information collected in this study will serve as a basis for the development of BAY3283142 for the treatment of people with CKD or NPDR. Participants may experience pain and discomfort when blood samples are taken. The researchers will closely monitor and manage any medical problems that the participants may have during the study.
This study plans to compare the accuracy of artificial intelligence (AI)-assisted fundus images with other ophthalmic devices such as optical coherence tomography (OCT) and fundus fluorescence angiography (FFA) in the diagnosis of diabetic retinopathy and diabetic macular edema.
The study used a new surgical technique: intraoperative fluorescence imaging,In the 1980s, some scholars proposed the concept of intraoperative fluorescein angiography.During vitrectomy, intraoperative fluorescein angiography under 3D microscope can guide the surgeon to observe the non-perfusion area and new blood vessels on the same screen for accurate retinal photocoagulation therapy.Through this technology, the primary retinal disease can be identified in time after the removal of vitreous hemorrhage during surgery, providing effective imaging evidence support for the design of further treatment.
Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients. This study aims to use a non-targeted metabolomics detection technique combined with ultra-high performance liquid chromatography time-of-flight mass spectrometry to analyze the metabolomics profile in aqueous humor sample of DR patents, and further explore the mechanism of the relationship between differential metabolites and their metabolic pathways with NLRP3 activation in DR inflammatory damage. DR patients with macular edema will receive anti-vascular endothelial growth factor (anti-VEGF) treatment; these patients will be divided into two groups: responders group and non-responders group.
An online survey (n=1,500) and 4 focus groups will be conducted with Latinx patients with diabetes (n=20) to obtain preliminary data regarding whether and how patient and clinician video testimonial interventions (n=6) increase eye health literacy and trust in healthcare.
Diabetic retinopathy is a common complication of diabetes and one of the leading causes of low vision and blindness in adults. In recent years, the prevalence of diabetes and the incidence of diabetic retinopathy have increased significantly in our country. Epidemiological studies show that the prevalence rate of diabetes in China is 12.8%, and the prevalence rate of DR in adult diabetic patients is 24.7%-37.5%, that is, there are about 3200-48 million DR patients in China, and the patients have a trend of younger people. DR has become a serious public health problem threatening people's lives and health. At present, it is known that the pathogenesis of DR is related to hypoxia, oxidative stress, inflammation, abnormal expression of cytokines and gene methylation, but the specific pathogenesis has not been fully clarified. Due to the hidden early symptoms of DR, the lack of basic screening conditions in primary medical and health institutions, and the lack of awareness of DR by patients themselves, many DR patients have already appeared serious retinopathy when they seek medical treatment, resulting in irreversible visual function impairment. In addition, the current clinical treatment methods for DR mainly include retinal photocoagulation therapy, intraocular anti-VEGF drug injection and vitrectomy surgery, etc. These methods are aimed at relatively severe diabetic retinopathy, and there is no effective treatment method for early diabetic retinopathy that can prevent or slow down the occurrence and development of DR. Therefore, to further explore the pathogenesis of DR and develop new therapeutic methods has become an urgent problem. Exosomes are extracellular vesicles secreted by living cells with a diameter of 40-150nm. With a bilayer lipid membrane structure, exosomes contain a variety of biomolecules such as lipids, proteins, nucleic acids, cytokines, and autoantigens, and are important mediators for the transmission of biological information between cells. Almost all cells can secrete exosomes, and exosomes from different cells have different functions. Exosomes transfer their contents to nearby or distant cells and participate in cell growth, angiogenesis, immune regulation and other processes. Previous studies have shown that exosomes secreted by various cells in the retina are present in the vitreous and aqueous humor of patients and play an important role in the pathogenesis of DR. At the same time, exosomes in the systemic circulation of diabetic patients can also reach the retina through the blood circulation, participate in the initiation process of DR And play an important role. At the same time, due to the double-layer lipid membrane structure, exosomes can also target the coated components to specific cells and tissues through biological barriers such as blood-brain and blood-eye, which is expected to become a highly efficient drug delivery route. Therefore, the role of exosomes in DR Treatment has also attracted much attention.
In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting complications from pars plana vitrectomy for diabetic vitreous hemorrhage with or without tractional retinal detachments.
Objective: Explore the biomarkers related to proliferative diabetic retinopathy by analyzing the protein expression profile changes of plasma exosomes in patients with difference phases of diabetic retinopathy, and investigate potential molecular mechanisms and therapeutic targets. Methods: Enrich exosomes from plasma by column extraction method. NTA, WB and TEM were used to characterize the obtained exosomes, and exosome proteinomics was performed by chromatography⁃mass spectrometry. Corhorts: The study was divided into four groups: a healthy control group, a diabetic without diabetic retinopathy group, a non-proliferative diabetic retinopathy group, and a proliferative diabetic retinopathy group, with 6 cases in each group.
The aim of the study is to analyse the risk factors involved in the development of diabetic retinopathy.